

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number  
WO 02/094816 A1(51) International Patent Classification<sup>7</sup>: C07D 403/10

(21) International Application Number: PCT/IN01/00205

(22) International Filing Date:  
20 November 2001 (20.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
403/MAS/2001 18 May 2001 (18.05.2001) IN(71) Applicant: AUROBINDO PHARMA LIMITED  
[IN/IN]; Plot No.2, Maitri Vihar Complex, Ameerpet,  
Hyderabad 500 038 (IN).(72) Inventors: RAMASHANKAR; Aurobindo Pharma Limited,  
Plot No. 2, Maitri Vihar Complex, Hyderabad 500 038  
(IN). REDDY RAVINDER, Vennapu; Aurobindo Pharma  
Limited, Plot No. 2, Maitri Vihar Complex, Hyderabad 500  
038 (IN). SIVAKUMARAN, Meenakshisunderam; Au-  
robindo Pharma Limited, Plot No. 2, Maitri Vihar Com-  
plex, Hyderabad 500 038 (IN). HANDA, Vijay, Kumar;  
Aurobindo Pharma Limited, Plot No. 2, Maitri Vihar Com-  
plex, Hyderabad 500 038 (IN).(74) Agent: RAJAGOPALAN, Krishnan; Rajagopalan & As-  
sociates, 15, Ganesh Chandra Avenue, 2nd Floor, Room  
No. 6, Calcutta 700 013 (IN).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).


## Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the fol-  
lowing designations AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,  
DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,  
ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ,  
TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,

[Continued on next page]

(54) Title: PROCESS FOR THE CRYSTALLIZATION OF LOSARTAN POTASSIUM



(I)

(57) Abstract: There is disclosed a process to prepare crystalline Form (I) of Losartan Potassium which comprises: i) Reacting compound of formula (I). Where "R" represents hydrogen or triphenylmethyl (trityl) protecting group with potassium hydroxide in an alcohol, and ii) Concentration under reduced pressure to remove alcohol, and iii) Adding an anti-solvent to isolate Losartan Potassium.



MD, RU, TJ, TM), European patent (AT, BF, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations of inventorship (Rule 4.17(iv)) for US only

**Published:**


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## PROCESS FOR THE CRYSTALLIZATION OF LOSARTAN POTASSIUM

**Field of the Invention:**

This invention relates to a crystallization process to obtain losartan Potassium polymorph



Form I. Losartan is used in the treatment of hypertension.

**Background of the Invention and Prior Art and Drawbacks:**

This invention relates to crystallization process to prepare Losartan Potassium Form I. Losartan Potassium is also known as 2-n-butyl-4-chloro-5-hydroxymethyl-1- [ [2'- (2H-tetrazole-5-yl) biphenyl-4-yl] methyl] imidazole potassium salt and is useful in the treatment of hypertension.

Losartan is known to inhibit the action of octapeptide hormone angiotensin II and is useful therefore in alleviating angiotensin induced hypertension. Further, it has been reported that losartan when administered with a diuretic such as furosemide or hydrochlorothiazide exhibits an enhanced anti-hypertensive effect. Administration of losartan with a non-steroidal anti-inflammatory drug can prevent renal failure.

Losartan is known to exhibit polymorphism (Ref: US Patent 5,608,075). Two polymorphic forms of Losartan Potassium, Form I and Form II have been reported in US Patent 5,608,075 along with their methods of preparation. Characterization of these two polymorphic forms has been described through applications of X-ray powder diffraction pattern, DSC thermograms, FTIR spectra, Raman spectra and solid state <sup>13</sup>C NMR.

Polymorph Form I has been prepared in US Patent 5,608,075 by adding an aqueous solution of Losartan Potassium to a refluxing mixture of isopropanol/cyclohexene and removing water by distilling cyclohexene/isopropanol/water ternary azeotrope at 64° C. Losartan Potassium Form I crystallizes out at 69° C.

In WO 98/18787, a process to prepare polymorph Form I has been disclosed wherein solution of potassium salt in aqueous isopropanol is heated to lower the water content to about 2.6% by removing isopropanol/water mixture, immense seeding with Losartan Potassium slurry in cyclohexene is done until the seed remains undissolved and removing water to 0.02-0.11% by

distilling out the ternary azeotrope while simultaneously adding cyclohexane. The crystallized material is recovered by filtration.


In both these disclosed processes, crystalline Losartan Potassium has been achieved from a mixture of isopropanol and cyclohexane and this crystalline material has been characterized as polymorph Form I. Crystallization process described in WO 98/18787 requires adequate precision to consistently obtain polymorph Form I and mixture of solvents, cyclohexane and isopropanol is difficult to separate. The inventors have surprisingly discovered that Losartan Potassium polymorph Form I can be prepared in one pot by reacting triphenylmethyl protected Losartan with Potassium hydroxide in methanol/acetone without isolating the free Losartan acid and requires no seeding.

**Detailed Description of the Invention:**

This invention relates to the process to manufacture Losartan Potassium Form I without use of isopropanol/cyclohexane solvent mixture. Typically Losartan free acid is suspended in a solvent and potassium hydroxide is added to obtain a clear solution, which is then concentrated under reduced pressure to remove most of the solvent. An anti-solvent is added to crystallize Losartan Potassium. The solvents to prepare Losartan Potassium include methanol, ethanol, butanol but preferably the salt formation is carried out in methanol. Anti-solvent is selected from common solvents such as ethyl acetate, acetonitrile, toluene and acetone but the preferred anti-solvent is acetone.

Losartan free acid or triphenylmethyl protected Losartan may be prepared using the reactions and techniques described in US Patent 5,138,069 and WO 93/10108.

Alternatively, 2-n-butyl-4-chloro-5-hydroxymethyl-1- [2'- [ (2-triphenylmethyl) tetrazole-5-yl] biphenyl-4-yl] methyl] imidazole (herein referred as Trityl Losartan), a key intermediate

**TRITYL LOSARTAN**

in the manufacture of Losartan is refluxed with Potassium hydroxide in an alcohol, preferably methanol, to perform deprotection and generate in situ Losartan Potassium which is then isolated in desired polymorph Form I by distilling methanol and adding an anti-solvent such as acetonitrile, toluene, ethyl acetate and preferably acetone. Both the reaction and the crystallization may be effected in the same reaction vessel, and no expensive separation techniques, such as extraction or isolation of Losartan free acid are necessary. Such a process of obtaining Losartan Potassium polymorph Form I directly from Trityl losartan is not reported hitherto in literature and hence constitutes an object of the present invention. Additionally, the described preparation is done essentially under anhydrous condition and thus avoids elaborate azeotropic distillation for water removal. The desired polymorph Form I Losartan Potassium is obtained directly, that is, without having to isolate the free Losartan acid, which results in increased efficiency and contributes to the lower production cost.

Typically, trityl losartan is dissolved in 6-8 times by volume in methanol and equimolar quantity of potassium hydroxide is added. The resulting mixture is refluxed for a few hours till disappearance of trityl losartan is observed. Tritanol is recovered by filtration and methanol is distilled under reduced pressure. Acetone is added to the residue and distillation is continued to remove last traces of methanol. Losartan Potassium is obtained as a free flowing slurry in acetone that is

filtered and dried. The differential scanning calorimetric analysis and X-ray powder diffraction pattern confirm this to be polymorphic modification I.

The following examples further illustrate the preparation of Losartan Potassium polymorph form I and are not to be construed as any limitation thereof.

#### Example 1

100 gm. (0.152 mol.) 2-n-butyl-4-chloro-5-hydroxymethyl-1- [2'- [ (2-triphenylmethyl) tetrazole-5-yl] biphenyl-4-yl] methyl] imidazole (Trityl Losartan) was suspended in 650 ml. methanol. 10 gm. of 85% potassium hydroxide (0.152 mol.) was added and the mixture was refluxed under nitrogen atmosphere for nearly 6 hours. The reaction mass was cooled to 8-10° C and trianol byproduct was removed by filtration and washed with 50 ml. chilled methanol. The filtrate was treated with 1 g. charcoal and filtered through celite. Methanol solution was then concentrated at 45-50° C to remove most of methanol. 200 ml. acetone was added and distillation continued under reduced pressure to reduce the volume to approximately 120 ml. The white crystalline slurry was cooled to room temperature, filtered and product washed with 50 ml. acetone and dried in vacuum oven to obtain Losartan Potassium. Yield: 60 g. (86.58% of theory). DSC analysis (Figure 1) and X-ray powdered diffraction pattern (Figure 2) comply with that reported for polymorph Form I.

#### Example 2

To a suspension of 5 gm. (11.82 m. mol.) 2-n-butyl-4-chloro-5-hydroxymethyl-1- [2'- [ (2H-tetrazole-5-yl) biphenyl-4-yl] methyl] imidazole (Losartan acid) in 25 ml. methanol, 0.75 g. (86%) (11.52 m. mol.) potassium hydroxide powder was added and mass stirred at ambient temperature to obtain an almost clear solution. This was filtered through celite and the clarified solution was concentrated to remove most of methanol at 45-50° C under reduced pressure. 25 ml. of acetone

was added and distillation continued to distil most of the methanol/acetone mixture. Residue was diluted with 25 ml. acetone and contents cooled to 20-25° C for 10 min and product filtered under nitrogen atmosphere and washed with 5 ml. acetone. Product was dried 55-60° C under reduced pressure to yield 4.88 g. (89.5% of theory) Losartan Potassium Form I (DSC, XRPD).

### Example 3

To a suspension of 5 gm. (11.82 m. mol.) of Losartan acid in 25 ml. dry ethanol was added 0.75 g. (86%) (11.52 m. mol.) potassium hydroxide powder and mass stirred at ambient temperature for 25 minutes to obtain a clear solution. Ethanol was removed at 45-50° C under reduced pressure. 25 ml. of acetone was added and distillation continued to distil ethanol/acetone mixture under reduced pressure. Residue was stirred with 25 ml. acetone at 20-25° C and product filtered under nitrogen atmosphere and washed with 10 ml. acetone. Product was dried 55-60° C under reduced pressure to yield 4.85 g. (89% of theory) Losartan Potassium Form I (DSC).

### Example 4

Losartan Potassium Form I was prepared from Losartan acid in methanol as described in Example 2 and ethyl acetate was used in place of acetone. Yield: 4.95 g. (91% of theory).

### Example 5

Losartan Potassium Form I was prepared from Losartan acid following the procedure described in Example 2 and acetonitrile was added as anti-solvent to isolate the product. Yield: 4.8 g. (88% of theory).



**Example 6**

To a suspension of 5 g. Losartan in 25 ml. n-butanol, 0.75 g. of 86% powdered potassium hydroxide was added and the mixture was stirred at 20-25° C to get a clear solution. n-butanol ethanol was distilled under reduced pressure at temperature below 70° C. 25 ml. acetone was added and distilled under reduced pressure. Finally the contents were stirred in 25 ml. acetone at 20-25° C and filtered to obtain Losartan Potassium Form I. Yield: 4.8 g. (88% of theory).

**Example 7**

Losartan Potassium was prepared by reacting Losartan acid in n-butanol with potassium hydroxide as described in Example 6 and the product was isolated as polymorph Form I by addition of ethyl acetate as anti-solvent in place of acetone. Yield: 4.85 g. (89% of theory).

**Example 8**

Losartan Potassium was prepared in n-butanol as given in Example 6 and Form I of Losartan Potassium was isolated with toluene. Yield: 4.9 g. (90% of theory).


**Example 9**

Losartan Potassium was prepared in n-butanol as described in Example 6 and Form I was obtained by adding acetonitrile. Yield: 4.8 g. (88% of theory).

**We claim:**

1. A process to prepare crystalline Form I of Losartan Potassium which comprises

i. Reacting compound of the formula.



Where "R" represents hydrogen or triphenylmethyl (trityl) protecting group with potassium hydroxide in an alcohol, and

ii. Concentration under reduced pressure to remove alcohol, and

iii. Adding an anti-solvent to isolate Losartan Potassium.

2. A process according to claim 1 wherein exactly one mole equivalent of potassium hydroxide as to the starting compound is used.

3. A process according to claim 1 wherein alcohol is selected from the group consisting of methanol, ethanol, propanol, butanol and mixtures thereof.

4. A process according to claim 1 wherein the anti-solvent is selected from the group consisting of acetone, ethyl acetate, acetonitrile, toluene and mixtures thereof.
5. A process according to claim 1 wherein in situ de-protection is carried out to produce Losartan Potassium.

Dated this 12th day of November, 2001




FIG. 1




FIG. 2

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PC1/IN 01/00205

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D403/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 138 069 A (CARINI DAVID J ET AL) 11 August 1992 (1992-08-11) cited in the application	1-3
Y	examples 89,316 ---	4,5
X	WO 93 10106 A (DU PONT ;MERCK & CO INC (US)) 27 May 1993 (1993-05-27) cited in the application	1-3
Y	examples 8,26 ---	1-5
Y	WO 98 18787 A (KENNEDY MICHAEL T ;BREEN PATRICK (US); LARSON KAREN A (US); MAHADE) 7 May 1998 (1998-05-07) cited in the application page 4, line 24 -page 5, line 8; claim 1; examples --- -/-	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

28 March 2002

Date of mailing of the international search report

09/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IN 01/00205

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 81336 A (FARKAS JEN & ODBLAC ; FISCHER JANOS (HU); BALLO ILDIKO (HU); CZIBUL) 1 November 2001 (2001-11-01) claims; examples -----	1-5

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 01/00205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5138069	A	11-08-1992	AT 113276 T 15-11-1994
			AU 599396 B2 19-07-1990
			AU 7559687 A 21-01-1988
			CA 1334092 A1 24-01-1995
			CY 1855 A 05-04-1996
			DE 3750687 D1 01-12-1994
			DE 3750687 T2 23-02-1995
			DK 359687 A 12-01-1988
			EP 0253310 A2 20-01-1988
			ES 2063734 T3 16-01-1995
			FI 873071 A ,B, 12-01-1988
			HK 55495 A 21-04-1995
			HU 45976 A2 28-09-1988
			HU 218461 B 28-08-2000
			IE 69984 B1 16-10-1996
			IL 83153 A 15-12-1991
			KR 9005020 B1 18-07-1990
			KR 9005045 B1 18-07-1990
			LU 88662 A9 01-12-1995
			LV 5486 A3 10-03-1994
			NO 176049 B 17-10-1994
			PT 85312 A ,B, 01-08-1987
			SU 1694062 A3 23-11-1991
			US 5128355 A 07-07-1992
			US 5153197 A 06-10-1992
			US 5155118 A 13-10-1992
			AT 151755 T 15-05-1997
			AT 164520 T 15-04-1998
			AU 2777189 A 13-07-1989
			CA 1338238 A1 09-04-1996
			DE 68927965 D1 22-05-1997
			DE 68927965 T2 24-07-1997
			DE 68928631 D1 07-05-1998
			DE 68928631 T2 22-10-1998
			DK 5189 A 08-07-1989
			EP 0324377 A2 19-07-1989
			EP 0733366 A2 25-09-1996
			ES 2100150 T3 16-06-1997
			ES 2117463 T3 01-08-1998
			FI 890070 A ,B, 08-07-1989
			GR 3024053 T3 31-10-1997
			HU 9500636 A3 28-11-1995
			IE 960772 L 07-07-1989
			JP 2795746 B2 10-09-1998
			JP 3501020 T 07-03-1991
			JP 7025738 B 22-03-1995
			KR 9107213 B1 20-09-1991
			LU 90266 A9 01-10-1998
			MD 28 B1 30-06-1994
			NO 177265 B 08-05-1995
WO 9310106	A	27-05-1993	US 5130439 A 14-07-1992
			US 5310928 A 10-05-1994
			US 5206374 A 27-04-1993
			AU 665388 B2 04-01-1996
			AU 3179293 A 15-06-1993
			CA 2123900 A1 27-05-1993
			CZ 9401205 A3 15-02-1995



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IN 01/00205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9310106 A		EP 0643704 A1	22-03-1995
		FI 942282 A	17-05-1994
		JP 8500323 T	16-01-1996
		KR 212257 B1	02-08-1999
		KR 212405 B1	15-03-2000
		NO 941857 A	18-07-1994
		SK 57994 A3	08-02-1995
		WO 9310106 A1	27-05-1993
		PL 171453 B1	30-04-1997
		PL 176124 B1	30-04-1999
WO 9818787 A	07-05-1998	AT 214388 T	15-03-2002
		AU 5089898 A	22-05-1998
		BR 9712390 A	31-08-1999
		CZ 9901515 A3	13-10-1999
		EP 0937068 A1	25-08-1999
		HR 970565 A1	31-08-1998
		JP 2000504343 T	11-04-2000
		JP 3249827 B2	21-01-2002
		SK 57099 A3	14-02-2000
		TW 411338 B	11-11-2000
		WO 9818787 A1	07-05-1998
		US 5859258 A	12-01-1999
WO 0181336 A	01-11-2001	AU 5499801 A	07-11-2001
		WO 0181336 A1	01-11-2001

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**